A Single-center, Randomized, Double-blind, Placebo-Controlled,Positive-Controlled, Dose-Escalation, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of a Single Dose Injection of KL0011034 Injection in Healthy Chinese Volunteers
Latest Information Update: 25 Mar 2026
At a glance
- Drugs KL 0011034 (Primary) ; Etomidate
- Indications Anaesthesia; Sedation
- Focus Adverse reactions
- Sponsors Kelun Pharmaceutical
Most Recent Events
- 25 Mar 2026 New trial record